Compare BWEN & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | MIRA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 50.3M |
| IPO Year | 2009 | 2023 |
| Metric | BWEN | MIRA |
|---|---|---|
| Price | $2.41 | $1.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 247.6K | 145.1K |
| Earning Date | 05-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.31 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $146,785,000.00 | N/A |
| Revenue This Year | $11.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.93 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.41 | $0.80 |
| 52 Week High | $4.15 | $2.45 |
| Indicator | BWEN | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 37.62 |
| Support Level | $2.29 | $1.15 |
| Resistance Level | $2.49 | $1.28 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 25.00 | 26.67 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.